Creatine as a Treatment for Depression

The familiar staple of athletic performance enhancement, creatine, is now the subject of burgeoning scientific inquiry into its potential to alleviate symptoms of depression. A comprehensive systematic review published in the esteemed journal Brain Medicine has delved into existing clinical research, seeking to ascertain whether this widely recognized supplement could offer therapeutic benefits by addressing the brain’s fundamental energy requirements. While the findings offer a glimmer of cautious optimism, they simultaneously underscore the considerable expanse of the unknown, presenting a complex tapestry of mixed results that leave the scientific community with more intriguing questions than definitive answers.

Unpacking the Nuances of a Novel Therapeutic Avenue

The systematic review, meticulously conducted by researchers led by Bassam Jeryous Fares of the University of Ottawa, eschewed the initiation of new experimental trials. Instead, it focused on a critical analysis of the available published literature, a methodological approach designed to synthesize existing knowledge and identify overarching trends. This rigorous examination led to the identification of six distinct published reports, encompassing five randomized controlled trials. These trials adhered to the gold standard of scientific inquiry, employing a placebo-controlled design where participants were unaware of whether they were receiving creatine or an inert substance, thereby minimizing potential bias.

The geographical distribution of these foundational studies is noteworthy, spanning diverse research landscapes in South Korea, the United States, Brazil, Israel, and India. Collectively, these trials initiated with 238 participants, a cohort subsequently divided into 126 individuals receiving creatine and 112 allocated to the placebo group. The average age of participants was approximately 36 years, with a notable overrepresentation of women; indeed, two of the five studies specifically enrolled exclusively female participants. The focus of these investigations varied: four trials centered on individuals diagnosed with major depressive disorder (MDD), while one study extended its scope to participants grappling with bipolar disorder who were experiencing a depressive episode. The inherent heterogeneity in the design and methodologies employed across these studies precluded a unified statistical analysis, compelling the researchers to evaluate each study on an individual basis.

A Divergent Landscape of Clinical Outcomes

The systematic review unearthed a decidedly divided picture regarding creatine’s efficacy in treating depressive symptoms. A bifurcated landscape emerged, with some studies reporting promising results while others yielded null findings.

Promising Signals from Specific Cohorts:

Two of the five analyzed trials, both exclusively involving women diagnosed with major depressive disorder, indicated that creatine supplementation conferred additional benefits when integrated into existing treatment regimens. In one such study, participants who concurrently received five grams of creatine daily alongside the selective serotonin reuptake inhibitor (SSRI) escitalopram demonstrated significantly greater reductions in depressive symptoms after an eight-week period compared to their counterparts who received escitalopram with a placebo. This improvement was deemed substantial by conventional statistical benchmarks, registering a Cohen’s d of 1.13 on the Hamilton Depression Rating Scale (HDRS), a widely recognized instrument for assessing depression severity. Furthermore, a greater proportion of participants in the creatine group achieved remission from their depressive symptoms.

In another encouraging trial, creatine was administered in conjunction with cognitive behavioral therapy (CBT). The findings revealed that participants who received creatine exhibited a more pronounced reduction in depression symptoms, as measured by a standard assessment scale, compared to those who underwent CBT with a placebo. These results suggest a potential synergistic effect between creatine and established psychotherapeutic interventions.

Absence of Benefit in Other Investigations:

Conversely, the remaining three trials failed to demonstrate any meaningful benefit of creatine supplementation for depressive symptoms. One study, in particular, reported that neither a daily dose of five grams nor ten grams of creatine per day led to any improvement in symptoms among individuals whose depression had proven resistant to pharmacological treatment. This finding is particularly significant as it suggests creatine may not be a panacea for treatment-resistant depression.

Another investigation focused on adolescent girls and found no discernible advantage of creatine over a placebo, even when various dosages were explored. This highlights the potential for age and sex-specific responses to creatine supplementation. A third trial, which included individuals diagnosed with bipolar disorder experiencing a depressive episode, also reported no significant improvement in symptoms following creatine administration.

A Crucial Safety Consideration Emerges

Beyond the efficacy debate, the review brought to light an important safety consideration. Two participants diagnosed with bipolar disorder who received creatine supplementation developed hypomania or mania. This observation is particularly salient, suggesting that creatine may elicit differential responses in individuals depending on their underlying psychiatric condition. This finding necessitates careful consideration and further investigation into the potential risks associated with creatine use in vulnerable populations, particularly those with bipolar disorder.

The Underlying Rationale: Creatine’s Role in Brain Energy Metabolism

The scientific rationale underpinning the investigation into creatine’s potential antidepressant effects is deeply rooted in the brain’s extraordinarily high energy demands. While creatine is most widely recognized for its crucial role in the rapid regeneration of adenosine triphosphate (ATP) – the universal cellular energy currency – within muscle tissue, the brain also relies heavily on this energy system for optimal functioning.

Pre-existing research has identified alterations in brain creatine metabolism among individuals diagnosed with mood disorders, prompting scientists to explore the hypothesis that disruptions in cellular energy production could indeed contribute to the pathophysiology of depression. Creatine’s involvement in cellular energy homeostasis within the brain is therefore a key area of focus.

Furthermore, emerging evidence suggests that creatine may also exert influence over key neurotransmitter systems implicated in mood regulation. Specifically, it may impact the levels and activity of dopamine and serotonin, two crucial neuromodulators that are also primary targets of many antidepressant medications. Disruptions in these neurotransmitter pathways are well-established contributors to depressive disorders.

However, it is imperative to underscore that the authors of the review emphasize that these connections remain largely theoretical at this juncture. The existing studies primarily reveal correlations rather than definitive causal links, and it is not yet proven that altered creatine metabolism directly causes depression. The complex etiology of depression involves a multitude of interconnected biological pathways, and creatine’s potential role is one piece of a much larger puzzle.

Bassam Jeryous Fares, the first author of the review and a student at the University of Ottawa’s Faculty of Medicine, articulated this nuanced perspective, stating, "The signal is interesting, but it is not a verdict. Two trials pointed one way and three pointed another. That is not the kind of evidence on which you change clinical practice. It is the kind that tells you the question is worth further exploration."

Nicholas Fabiano, the corresponding author and a psychiatry resident at the University of Ottawa, echoed this sentiment of cautious optimism, urging restraint in drawing premature conclusions. "Creatine appears to be a safe intervention," he noted. "The adverse events we found were limited to mild gastrointestinal discomfort. We cannot yet reliably say that creatine helps with depressive symptoms or if the findings are generalizable to everyone."

The Imperative for Larger, More Robust Studies

The researchers involved in this comprehensive review unequivocally stress that the current body of evidence is too limited to warrant the routine clinical use of creatine for the treatment of depression. The existing clinical trials, while valuable, suffer from several limitations that temper their generalizability. These include relatively small sample sizes, a disproportionate representation of women compared to men, and considerable variability in methodological quality.

An assessment of bias within the studies revealed that only two trials were judged to have a low risk of bias, while the remaining three raised certain concerns, primarily pertaining to the methods of participant assignment and the handling of missing data. Consequently, the findings from these studies cannot be broadly applied to the general population without further validation.

In light of these limitations, the review authors advocate for a concerted effort to conduct larger, longer-term clinical trials. These future studies should extend beyond the typical eight-week duration observed in the analyzed trials, allowing for a more comprehensive evaluation of creatine’s sustained effects. Researchers also recommend investigating creatine’s efficacy in conjunction with established interventions such as exercise, a synergistic approach that holds promise for mental health. Furthermore, exploring whether different dosages of creatine yield varied outcomes is crucial, while simultaneously acknowledging that higher doses do not necessarily equate to greater benefits and may increase the risk of adverse effects.

Intriguingly, findings from animal studies may offer a valuable clue to understanding the differential responses observed in human trials. Experiments in rodent models have demonstrated that creatine can influence depression-like behaviors differently in male and female subjects. This sex-specific effect in animal models could potentially help explain why the human studies that yielded the strongest positive results predominantly involved female participants.

For the present, creatine remains an intriguing possibility in the realm of mental health, rather than a proven therapeutic intervention. A supplement long associated with the augmentation of physical performance is now capturing the growing interest of scientists who are actively seeking novel and effective strategies for the treatment of depression, a complex and pervasive global health challenge.

The peer-reviewed research article, titled "Creatine as a Treatment for Depression," was published in Brain Medicine and became available through Open Access on June 30, 2026, marking a significant step in the ongoing scientific exploration of this multifaceted compound. The implications of future research could potentially reshape our understanding of nutritional interventions in psychiatric care.